# Baird Downgrades Insulet to Neutral and Cuts Price Target to $158

By Token Post

Canonical URL: https://www.tokenpost.com/news/insights/62347
Published: 2026-11-20T21:56:12.000Z
Updated: 2026-11-20T21:56:12.000Z
Section: Insights & Views

> The firm lowered its target from $200 after a survey found weaker brand loyalty to automated insulin delivery systems than in the past.

Baird downgraded Insulet to Neutral from Overweight and cut its price target to $158 from $200 after a survey found weaker brand loyalty to automated insulin delivery systems than in the past.

The revised target represented about 19% upside from Friday’s close.


